ClinicalTrials.gg
CompletedNCT00777608Updated Aug 25, 2015Results posted

A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)

A Phase 1 interventional study of Comparator: Placebo 5mg (run in) and Donepezil 5 - 10 mg in Alzheimer's Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2015-08-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Alzheimer Disease by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Merck & Co., Inc.

Enrollment
9th of 29
106 · median 34
Started
2008
with 1 other
Phase 1
18 of 31
none open now
Registered
7th of 31
by date

Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, this one is the 9th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2008, is one of 18 in phase 1, and was the 7th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 31 studies in Alzheimer Disease by Merck & Co., Inc is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Alzheimer Disease by Merck & Co., Inc, or all of them as a file.
02

Study summary

This study will evaluate the performance of the CogState computerized neuropsychological battery, Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) in participants with mild-to-moderate Alzheimer's disease (AD).

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is ambulatory, male or female and 55 years of age or older
  • Participant has reliable informant/caregiver who can communicate effectively with the study site and personnel

Exclusion criteria

Exclusion Criteria:

  • Participant has a history within the last 6 months or current evidence of a psychotic disorder or an active major depressive disorder or participant has any history of schizophrenia
  • Participant has a history of multiple and/or serious allergies to drugs or food or a history of an allergic reaction to more than 3 drug classes
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Donepezil 5-10 mg

    There will be a 14 day period when all participants will receive placebo, followed by 5 mg donepezil, once daily for 14 days then titrated to 10 mg donepezil once daily for 70 days. Participants may then receive open-label donepezil for an additional 24 weeks.

    Drug: Comparator: Placebo 5mg (run in) · Drug: Donepezil 5 - 10 mg · Drug: Donepezil 10 mg

  • Placebo comparator
    Placebo

    There will be a 14 day period when all participants will receive placebo. Participants will take placebo capsules orally, once daily for 84 days. Participants may then receive open-label donepezil for an additional 24 weeks.

    Drug: Comparator: Placebo 5mg (run in) · Drug: Comparator: Placebo 5-10 mg · Drug: Donepezil 10 mg

Interventions

  • DrugComparator: Placebo 5mg (run in)

    Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.

  • DrugDonepezil 5 - 10 mg

    Donepezil 1 capsule (5 mg) orally, once daily for 14 days. Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).

  • DrugComparator: Placebo 5-10 mg

    Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days. Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).

  • Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).

06

What researchers measure

Primary outcomes

  1. Change in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4

    CogState is a simple, brief computerized neuropsychological battery to evaluate cognitive impairments characterizing mild-to-moderate Alzheimer's Disease (AD). The composite CogState assesses attention and memory functions - including Verbal episodic memory, Visual Episodic Memory, Psychomotor function, Visual attention and working memory. CogState scores are measured on a linear scale (with no maximum score) and a reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change in the CogState Composite Score at Week 4 compared to baseline.

    Time frame: Baseline and 4 weeks

Secondary outcomes

  1. Evaluate the Efficacy of Donepezil by Determining the Change in Mean CogState Composite Score at Week 2, Week 8 and Week 12

    CogState is a simple, brief computerized neuropsychological battery to evaluate cognitive impairments characterizing mild-to-moderate Alzheimer's Disease (AD). The composite CogState assesses attention and memory functions - including Verbal episodic memory, Visual Episodic Memory, Psychomotor function, Visual attention and working memory. CogState scores are measured on a linear scale (no maximum score) and a reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change from baseline in the CogState Composite Score at Weeks 4, 8 and 12.

    Time frame: Baseline and 2 weeks, 8 weeks and 12 weeks

  2. Evaluate the Efficacy of Donepezil by Determining the Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score at Week 4, Week 8 and Week 12

    The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation and praxis using an 11-point AD Assessment Scale. It has a minimum score of 0 and a maximum severity score of 70, and a higher score indicates more impairment. A reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change in the ADAS-Cog score at Weeks 4, 8 and 12 compared to baseline.

    Time frame: Baseline and 4 weeks, 8 weeks and 12 weeks.

07

Results

Posted Feb 24, 2011

Participant flow

Participant flow — Overall Study
MilestoneDonepezil 5-10 mgPlacebo
Started5353
Completed4947
Not completed46
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject13
Withdrew: Protocol violation10
Withdrew: Investigator decision12

Outcome measures

PrimaryChange in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4

CogState is a simple, brief computerized neuropsychological battery to evaluate cognitive impairments characterizing mild-to-moderate Alzheimer's Disease (AD). The composite CogState assesses attention and memory functions - including Verbal episodic memory, Visual Episodic Memory, Psychomotor function, Visual attention and working memory. CogState scores are measured on a linear scale (with no maximum score) and a reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change in the CogState Composite Score at Week 4 compared to baseline.

Time frame:
Baseline and 4 weeks
Reported as:
Least squares mean · Score on a scale
Change in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4
Score on a scaleDonepezil 5-10 mgPlacebo
Change in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4-0.10 ± 0.07-0.07 ± 0.06
Statistical analysis
  • Donepezil 5-10 mg vs Placebo · ANOVA · p = 0.231 · Mean difference (final values): -0.07 · 90% CI -0.2 to 0.08
SecondaryEvaluate the Efficacy of Donepezil by Determining the Change in Mean CogState Composite Score at Week 2, Week 8 and Week 12

CogState is a simple, brief computerized neuropsychological battery to evaluate cognitive impairments characterizing mild-to-moderate Alzheimer's Disease (AD). The composite CogState assesses attention and memory functions - including Verbal episodic memory, Visual Episodic Memory, Psychomotor function, Visual attention and working memory. CogState scores are measured on a linear scale (no maximum score) and a reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change from baseline in the CogState Composite Score at Weeks 4, 8 and 12.

Time frame:
Baseline and 2 weeks, 8 weeks and 12 weeks
Reported as:
Least squares mean · Score on a scale
Evaluate the Efficacy of Donepezil by Determining the Change in Mean CogState Composite Score at Week 2, Week 8 and Week 12
Score on a scaleDonepezil 5-10 mgPlacebo
Week 2 (N=38, N=43)-0.2 ± 0.07-0.006 ± 0.06
Week 8 (N=38, N=40)-0.1 ± 0.07-0.02 ± 0.07
Week 12 (N=38, N=41)-0.2 ± 0.07-0.09 ± 0.07
Statistical analysis
  • Donepezil 5-10 mg vs Placebo · ANOVA · p = 0.041 · Mean difference (final values): -0.2 · 90% CI -0.3 to -0.008Statistical analysis for Week 2
  • Donepezil 5-10 mg vs Placebo · ANOVA · p = 0.143 · Mean difference (final values): -0.1 · 90% CI -0.3 to 0.06Statistical analysis for Week 8
  • Donepezil 5-10 mg vs Placebo · ANOVA · p = 0.226 · Mean difference (final values): -0.07 · 90% CI -0.2 to 0.09Statistical analysis for Week 12
SecondaryEvaluate the Efficacy of Donepezil by Determining the Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score at Week 4, Week 8 and Week 12

The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation and praxis using an 11-point AD Assessment Scale. It has a minimum score of 0 and a maximum severity score of 70, and a higher score indicates more impairment. A reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change in the ADAS-Cog score at Weeks 4, 8 and 12 compared to baseline.

Time frame:
Baseline and 4 weeks, 8 weeks and 12 weeks.
Reported as:
Least squares mean · Score on a scale
Evaluate the Efficacy of Donepezil by Determining the Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score at Week 4, Week 8 and Week 12
Score on a scaleDonepezil 5-10 mgPlacebo
Week 4 (N=38, N=43)0.2 ± 0.8-0.3 ± 0.7
Week 8 (N=37, N=40)0.07 ± 1.0-0.7 ± 1.0
Week 12 (N=38, N=40)-1.4 ± 1.0-1.0 ± 1.0
Statistical analysis
  • Donepezil 5-10 mg vs Placebo · ANOVA · p = 0.324 · Mean difference (final values): 0.5 · 90% CI -1.2 to 2.2Statistical analysis for Week 4
  • Donepezil 5-10 mg vs Placebo · ANOVA · p = 0.285 · Mean difference (final values): 0.8 · 90% CI -1.5 to 3.1
  • Donepezil 5-10 mg vs Placebo · ANOVA · p = 0.401 · Mean difference (final values): -0.3 · 90% CI -2.6 to 1.9Statistical analysis for Week 12

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donezepil 5-10 mg—3/53 (5.7%)10/53 (18.9%)
Placebo—0/53 (0%)9/53 (17%)
Most frequent serious events
Most frequent serious events
EventDonezepil 5-10 mgPlacebo
Inguinal herniaGastrointestinal disorders1/530/53
Head InjuryInjury, poisoning and procedural complications1/530/53
Subdural haematomaInjury, poisoning and procedural complications1/530/53
ConvulsionNervous system disorders1/530/53
Urinary incontinenceRenal and urinary disorders1/530/53
Most frequent other events
Most frequent other events
EventDonezepil 5-10 mgPlacebo
NauseaGastrointestinal disorders7/535/53
DizzinessNervous system disorders3/534/53

Baseline characteristics

Age, Customized
Age, Customized(Participants)Donepezil 5-10 mgPlaceboTotal
Number5353106
Sex: Female, Male
Sex: Female, Male(Participants)Donepezil 5-10 mgPlaceboTotal
Female232245
Male303161
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Oct 2009 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2008
First posted
Oct 22, 2008
Start
Dec 2008
Primary completionActual
Oct 2009
CompletionActual
Apr 2010
Results first posted
Feb 24, 2011
Last update
Aug 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00777608
Responsible party
Sponsor
First posted
Oct 22, 2008
Start date
Dec 2008
Primary completion
Oct 2009
Completion
Apr 2010
Results posted
Feb 24, 2011
Last update
Aug 25, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion